THE ANALYSIS STUDY OF INTERVENTIONS FOR DRY EYES: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/hamfeh88Keywords:
Cyclosporine, dietary supplement, dry eyes syndrome, intense pulse light, NOV03, perfluorohexyloctane, tear film lipid layerAbstract
Introduction: Dry eye disease (DED) results from dysregulated ocular inflammation, causingpersistent ocular surface dysfunction, with a global surge in prevalence, especially among children andadolescents, due to increased technology use. Beyond significant ocular morbidity, DED's association with systemic autoimmune disorders, impact on quality of life, and links to psychological and sleep disorders underscore its extensive repercussions. This systematic review aims to comprehensively explore an integrated approach to managing DED, emphasizing preventive and promotive strategies across various levels of healthcare.
Method: The researchers in this study followed the 2020 PreferredReporting Items for Systematic Review and MetaAnalysis (PRISMA) guidelines to ensure that their work met the required standards. This was done to ensure the precision and reliability of the conclusionsderived from the research.
Result: This systematic review investigated final 15 articles. After looking at the titles and summaries, we found 6 papers that fit our criteria. At first, we excluded several articlesbecause they were written in review style and case reports. But after reading the full papers carefully, we included four papers inour final analysis. These papers included a retrospective observational study,prospective study, and double-blind, randomized, placebo-controlled trial, and prospective interventional pilot study.
Conclusion: In summary, a study suggests that OPT-IPL (Optilight Intense Pulse Light) treatment enhances tear film lipid layer (TFLL) and improves signs and symptoms of dryeye disease (DED) by enhancing meibomian gland function. The phase 3 trial with NOV03 provides compelling evidence of reduced DED signs and symptoms over 8 weeks, demonstrating statistical andclinical significance, with good tolerability. Additionally, the ESSENCE-2 trial highlights the efficacyof a water-free cyclosporine solution in improving ocular surface staining associated with DED, showcasing potential advantages over existing therapies. Our study revealed promising and safe outcomes for dietary supplementation, which preserved tear production in a rat dry eye model and showed significant improvements in both objective parameters and subjective dry eye symptoms. However, further data is needed to validate its widespread use as a common intervention.
References
Craig J.P., Nichols K.K., Akpek E.K., Caffery B., Dua H.S., Joo C.K., Liu Z., Nelson J.D., Nichols J.J., Tsubota K., et al.TFOS DEWS II Definition and Classification Report. Ocul. Surf.2017;15:276–283. doi:10.1016/j.jtos.2017.05.008. [PubMed][CrossRef] [Google Scholar]
Stapleton F., Alves M., Bunya V.Y., JalbertI., Lekhanont K., Malet F., Na K.S., Schaumberg D., Uchino M. Vehof J., et al. TFOS DEWS II Epidemiology Report. Ocul. Surf. 2017;15:334–365. doi:10.1016/j.jtos.2017.05.003. [PubMed][CrossRef] [Google Scholar]
Moon J.H., Kim K.W., Moon N.J. Smartphone use is a risk factor for pediatricdry eye disease according to region and age: A case control study Pediatrics and Strabismus. BMC Ophthalmol. 2016;16 doi: 10.1186/s12886-0160364-4. [PMCfree article] [PubMed] [CrossRef] [GoogleScholar]
Uchino M., Yokoi N., Uchino Y., Dogru M., Kawashima M., Komuro A., SonomuraY., Kato H., Kinoshita S., Schaumberg D.A., et al. Prevalence of dry eye disease and its risk factors in visual displayterminal users: The Osaka study. Am. J. Ophthalmol. 2013;156 doi: 10.1016/j.ajo.2013.05.040. [PubMed] [CrossRef] [Google Scholar]
Dana R., Bradley J.L., Guerin A., Pivneva I., Stillman I.Ö., Evans A.M., Schaumberg
D.A. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. Am. J. Ophthalmol. 2019;202:47–54.doi:10.1016/j.ajo.2019.01.026. [PubMed]
[CrossRef] [Google Scholar]
Donthineni P.R., Kammari P., ShanbhagS.S., Singh V., Das A.V., Basu S. Incidence, demographics, types and riskfactors of dry eye disease in India: Electronic medical records driven big data analytics report I. Ocul. Surf. 2019 doi:10.1016/j.jtos.2019.02.007. [PubMed][CrossRef] [Google Scholar]
Song, Y., Yu, S., He, X., Yang, L., Wu, Y.,Qin, G., … Pazo, E. E. (2021). Tear film interferometry assessment after intensepulsed light in dry eye disease: A randomized, single masked, sham- controlled study. Contact Lens and Anterior Eye 101499. doi:10.1016/j.clae.2021.101499
Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.Ophthalmology. 2023;130(5):516-524.doi:10.1016/j.ophtha.2022.12.021
Akpek EK, Wirta DL, Downing JE, et al. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial. JAMA Ophthalmol.2023;141(5):459 466.doi:10.1001/jamaophthalmol.2023.0709
Motoko Kawashima, Shigeru Nakamura,Yusuke Izuta, Sachiko Inoue, Kazuo Tsubota, Dietary Supplementation with a Combination of Lactoferrin, Fish Oil, and Enterococcus faecium WB2000 forTreating Dry Eye: A RatModel and Human Clinical Study, The Ocular Surface, Volume 14, Issue 2, 2016, Pages 255-263, ISSN 1540124,https://doi.org/10.1016/j.jtos.2015.12.005.(https://www.sciencedirect.com/science/artile/pii/S1542012416000069.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
